Molecular Imaging Insight visits pioneers across the country to determine how molecular imaging is improving detection, risk stratification and treatment of coronary artery disease.

As researchers continue to explore the role of stem cell therapy in cardiac medicine, molecular imaging will take center stage. Thats because transplanted cells must be tracked and monitored in vivo. Here is a closer look at various clinical trials focused on the potential of cardiac stem cell therapies that offer a better understanding of how various molecular imaging modalities will contribute to and measure the eventual clinical utility of cardiac stem cell-based therapies.

In an era that is becoming more focused on the need for developing evidence-based and personalized medicine, molecular imaging provides a detailed look into human physiology and disease at the cellular and molecular level.

Molecular Imaging Insight spoke with three experts to discuss the evidence supporting a coverage expansion, reaction to CMS proposed decision memo and speculate on what the final verdict might be.

Diagnostic imaging modalities utilized in the care of cancer patients must fulfill several requirements: they must diagnose and characterize tumors with a high accuracy, must reliably stage and restage the disease and should allow for monitoring the effects of therapeutic interventions on the course of the disease. Ideally, imaging enables physicians to predict treatment responses before therapies are initiated. They should impact patient management by guiding treating physicians to appropriate, individualized treatment strategies. There is ample evidence that positron emission tomography (PET) and PET/CT imaging meet these requirements.

New integrated imaging for brain tumors offers insight into tumor metabolism

As personalized medicine attempts to revolutionize healthcare, giving patients access to tailored medical care, PET/CT is emerging with the promise of personalized therapies for oncology, including womens cancers to provide the right patient with the right treatment at the right time.

The next generation of molecular imaging technology is here. Pioneers plan to deploy integrated molecular imaging early next year. This newest solution takes a new approach. Siemens Medical Solutions Biograph mCT (molecular CT) unites top-of-the-line molecular imaging components such as ultraHDPET technologyHDPET and time-of-flight, combined with advanced CT capabilities up to 128 slices to offer dramatic clinical and throughput improvements. The system, which shows the sum of CT and PET is greater than its parts, also provides increased flexibility and speed, key metrics in todays tight fiscal climate.